Aurobindo Pharma Ltd. on Tuesday said it has set April 23 as the opening date for its ₹800 crore buyback offer.

The closing date for the buyback is April 29, Aurobindo Pharma said in a regulatory filing.

Earlier on April 6, the company's board had approved buyback of up to 54,23,728 fully paid-up equity shares having a face value of ₹1 each at a price of ₹1,475 per share for an aggregate amount up to ₹800 crore on a proportionate basis through the tender offer route.

The company has set April 17 as the record date for determining the entitlement and the names of equity shareholders who would be eligible to participate in the buyback.

The buyback size constitutes 3.93% and 2.62% of the aggregate of the total paid-up equity share capital and free reserves (including securities premium) of the company as per the audited standalone and consolidated financial statements of the Company as at March 31, 2025, respectively, the filing said.

In its letter to shareholders, Aurobindo Pharma said the buyback will help it reward shareholders and enhance the overall return to them, while it is expected to improve earnings per share and other key ratios such as return on net worth and return on assets over a period of time.

The buyback will not result in a change in control or otherwise affect the existing management structure of the company, it added.